The 10-second takeaway
For the quarter ended Nov. 30 (Q2), AngioDynamics beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased, and earnings per share dropped significantly.
Margins dropped across the board.
AngioDynamics reported revenue of $58 million. The five analysts polled by S&P Capital IQ foresaw revenue of $56 million. Sales were 8.9% higher than the prior-year quarter's $53 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.13. The six earnings estimates compiled by S&P Capital IQ predicted $0.12 per share on the same basis. GAAP EPS of $0.09 for Q2 were 31% lower than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 57.2%, 190 basis points worse than the prior-year quarter. Operating margin was 9.2%, 240 basis points worse than the prior-year quarter. Net margin was 4.0%, 210 basis points worse than the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods.
What does the future hold?
Next quarter's average estimate for revenue is $53 million. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $219 million. The average EPS estimate is $0.42.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 89 members out of 105 rating the stock outperform, and 16 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give AngioDynamics a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is hold, with an average price target of $15.43.
- Add AngioDynamics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Cardiac-Care Stocks That Could Bring Heart-Stopping Gains
Investors hit the jackpot with cardiac-care stocks last year. Here are three stocks primed to continue the heart-stopping gains.
A Trio of Stock Prospects in Medical Devices
What is the outlook for AngioDynamics, DexCom, and Abiomed?
Will AngioDynamics Earnings Rise With Its Soaring Stock?
MAKO and Intuitive Surgical's successes have overshadowed this small medical-device maker, but its shares have risen to two-year highs. Will AngioDynamics earnings live up to the company's promise?